ES2523740T3 - Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2 - Google Patents

Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2 Download PDF

Info

Publication number
ES2523740T3
ES2523740T3 ES09825523.5T ES09825523T ES2523740T3 ES 2523740 T3 ES2523740 T3 ES 2523740T3 ES 09825523 T ES09825523 T ES 09825523T ES 2523740 T3 ES2523740 T3 ES 2523740T3
Authority
ES
Spain
Prior art keywords
cdr
receptor
growth factor
fibroblast growth
monoclonal antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09825523.5T
Other languages
English (en)
Inventor
Kyung Jin Kim
Wei-Meng Zhao
Hangil Park
Maximiliano Vasquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galaxy Biotech LLC
Original Assignee
Galaxy Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech LLC filed Critical Galaxy Biotech LLC
Application granted granted Critical
Publication of ES2523740T3 publication Critical patent/ES2523740T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un anticuerpo monoclonal (mAb) que se une al receptor del factor de crecimiento de fibroblastos 2 (FGFR2), en donde el mAb comprende tres CDR de la cadena ligera que tienen las secuencias de aminoácidos KASQGVSNDVA (CDR-L1), SASYRYT (CDR-L2) y QQHSTTPYT (CDR-L3) respectivamente; y tres CDR de la cadena pesada que tienen las secuencias de aminoácidos TYNVH (CDR-H1), SIYPDNGDTSYNQNFKG (CDR-H2) y GDFAY (CDR-H3) respectivamente.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14

Claims (1)

  1. imagen1
ES09825523.5T 2008-11-07 2009-11-06 Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2 Active ES2523740T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11268608P 2008-11-07 2008-11-07
US112686P 2008-11-07
US16487009P 2009-03-30 2009-03-30
US164870P 2009-03-30
PCT/US2009/063647 WO2010054265A2 (en) 2008-11-07 2009-11-06 Monoclonal antibodies to fibroblast growth factor receptor 2

Publications (1)

Publication Number Publication Date
ES2523740T3 true ES2523740T3 (es) 2014-12-01

Family

ID=42153600

Family Applications (3)

Application Number Title Priority Date Filing Date
ES14188785.1T Active ES2646168T3 (es) 2008-11-07 2009-11-06 Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
ES09825523.5T Active ES2523740T3 (es) 2008-11-07 2009-11-06 Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
ES17191118T Active ES2770134T3 (es) 2008-11-07 2009-11-06 Anticuerpos monoclonales para el receptor del factor de crecimiento de fibrolastos 2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES14188785.1T Active ES2646168T3 (es) 2008-11-07 2009-11-06 Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17191118T Active ES2770134T3 (es) 2008-11-07 2009-11-06 Anticuerpos monoclonales para el receptor del factor de crecimiento de fibrolastos 2

Country Status (21)

Country Link
US (8) US8101723B2 (es)
EP (4) EP3290052B1 (es)
JP (7) JP5627591B2 (es)
KR (1) KR101699432B1 (es)
CN (1) CN102131524B (es)
AU (1) AU2009313357B2 (es)
BR (1) BRPI0917315B8 (es)
CA (2) CA3166399A1 (es)
DK (3) DK3290052T3 (es)
ES (3) ES2646168T3 (es)
HK (3) HK1160012A1 (es)
HR (2) HRP20171640T1 (es)
HU (1) HUE035700T2 (es)
LT (2) LT2842573T (es)
MX (1) MX2011000455A (es)
NO (1) NO2842573T3 (es)
PL (3) PL2365828T3 (es)
PT (3) PT2365828E (es)
RU (1) RU2546254C9 (es)
SI (2) SI3290052T1 (es)
WO (1) WO2010054265A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US20110059091A1 (en) * 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
DK3290052T3 (da) 2008-11-07 2020-02-03 Galaxy Biotech Llc Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
RU2012153241A (ru) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
EP2603521A4 (en) * 2010-08-12 2014-10-01 Attogen Inc ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
CN104254342A (zh) * 2011-12-14 2014-12-31 西雅图基因公司 新抗体药物缀合物(adc)及其用途
MY170407A (en) * 2012-03-08 2019-07-27 Crucell Holland Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
NZ631445A (en) 2012-04-09 2017-02-24 Daiichi Sankyo Co Ltd Anti-fgfr2 antibody
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
HUE042184T2 (hu) * 2012-12-21 2019-06-28 Janssen Biotech Inc Érzékeny multiplex immunvizsgálati eljárás szolúbilis fibroblaszt növekedési faktor receptorok kimutatására
CN103145843B (zh) * 2013-02-20 2014-10-29 暨南大学 抗成纤维细胞生长因子受体的单链抗体
MX2015011428A (es) 2013-03-06 2016-02-03 Genentech Inc Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
TWI679021B (zh) * 2013-08-01 2019-12-11 美商戊瑞治療有限公司 無海藻糖基化抗fgfr2iiib抗體
JP6509735B2 (ja) * 2013-10-08 2019-05-08 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤の組合せ
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法
CN104231079A (zh) * 2014-09-12 2014-12-24 暨南大学 一种靶向bFGF高亲和力受体结合位点的抗体及其应用
WO2016163433A1 (ja) * 2015-04-08 2016-10-13 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤を含む組成物
US10881734B2 (en) 2015-04-20 2021-01-05 Daiichi Sankyo Company, Limited Monoclonal antibodies to human fibroblast growth factor receptor 2 (HFGFR2) and methods of use thereof
RU2638457C2 (ru) * 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
CN108368174B (zh) * 2015-11-23 2023-04-14 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
JP7299842B2 (ja) 2017-05-16 2023-06-28 ファイヴ プライム セラピューティクス インク がん治療における化学療法剤と組み合わせた抗ｆｇｆｒ２抗体
NZ759601A (en) 2017-06-02 2023-06-30 Merck Patent Gmbh Aggrecan binding immunoglobulins
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
US10899843B2 (en) 2017-10-24 2021-01-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
TW201922782A (zh) 2017-10-24 2019-06-16 美商麥珍塔治療學股份有限公司 去除cd117+細胞之組合物及方法
US20220010020A1 (en) 2018-10-05 2022-01-13 Five Prime Therapeutics, Inc. Anti-FGFR2 Antibody Formulations
EP4081547A4 (en) * 2019-12-24 2024-02-21 Dizal Jiangsu Pharmaceutical Co Ltd NOVEL ANTI-FGFR2B ANTIBODIES
CN116367855A (zh) * 2020-06-03 2023-06-30 博德研究所 特异型性结合成纤维细胞生长因子受体2的拮抗性双互补位抗体及其使用方法
KR20230095070A (ko) 2020-10-22 2023-06-28 리제너론 파마슈티칼스 인코포레이티드 항-fgfr2 항체 및 이의 사용 방법
WO2022143728A1 (zh) * 2020-12-29 2022-07-07 深圳福沃药业有限公司 抗fgfr2抗体及其用途
WO2023056916A1 (zh) * 2021-10-08 2023-04-13 深圳福沃药业有限公司 Adcc增强型抗fgfr2抗体及其用途
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
WO2024067876A1 (en) * 2022-09-30 2024-04-04 3H Pharmaceuticals Co., Ltd. Anti-fgfr2b antibodies and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0481000T3 (da) * 1989-07-06 1999-11-15 Univ California Receptorer for fibroblastvækstfaktorer
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5863888A (en) * 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU3494397A (en) 1996-06-18 1998-01-07 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fibroblast growth factor receptor activating gene i and related compositions and methods
US20030143676A1 (en) 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
KR100945108B1 (ko) * 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
AU2002314495A1 (en) 2001-06-20 2003-01-02 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
DK1469878T3 (da) 2002-01-31 2011-07-18 Max Planck Gesellschaft FGFR agonister
KR100493460B1 (ko) * 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
PL1648998T3 (pl) 2003-07-18 2015-03-31 Amgen Inc Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
US20070248605A1 (en) * 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
EP1773305A2 (en) * 2004-05-25 2007-04-18 Yale University Corporation Method for treating skeletal disorders resulting from fgfr malfunction
EP2041575A2 (en) 2006-03-31 2009-04-01 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US8945572B2 (en) * 2006-05-12 2015-02-03 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
JP4560582B2 (ja) 2006-06-02 2010-10-13 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
CA2654025C (en) 2006-06-02 2016-08-02 Xoma Technology Ltd. Hepatocyte growth factor (hgf) binding proteins
EP2046384A4 (en) 2006-06-15 2009-12-02 Fibron Ltd ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
AU2007315211B2 (en) * 2006-11-03 2013-01-17 U3 Pharma Gmbh FGFR4 antibodies
ES2600882T3 (es) * 2007-03-23 2017-02-13 The Translational Genomics Research Institute Procedimiento de clasificación del cáncer de endometrio
US20110091473A1 (en) 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
DK3290052T3 (da) 2008-11-07 2020-02-03 Galaxy Biotech Llc Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
US20120301482A1 (en) 2009-08-25 2012-11-29 National Jewish Health Methods and compositions for treatment of lung injury

Also Published As

Publication number Publication date
US8603987B2 (en) 2013-12-10
PT2365828E (pt) 2014-12-12
WO2010054265A2 (en) 2010-05-14
JP2020096615A (ja) 2020-06-25
LT3290052T (lt) 2020-02-25
PT3290052T (pt) 2020-02-06
JP6960485B2 (ja) 2021-11-05
JP2012508184A (ja) 2012-04-05
RU2546254C2 (ru) 2015-04-10
KR20110081141A (ko) 2011-07-13
EP3290052A1 (en) 2018-03-07
US20190153105A1 (en) 2019-05-23
HRP20200090T1 (hr) 2020-04-03
BRPI0917315B8 (pt) 2021-05-25
SI3290052T1 (sl) 2020-07-31
US20140193899A1 (en) 2014-07-10
HK1160012A1 (en) 2012-08-10
JP6342223B2 (ja) 2018-06-13
US20160362496A1 (en) 2016-12-15
NO2842573T3 (es) 2018-02-24
CN102131524B (zh) 2014-05-14
HK1207974A1 (en) 2016-02-19
JP2022008996A (ja) 2022-01-14
US20120134994A1 (en) 2012-05-31
DK3290052T3 (da) 2020-02-03
CN102131524A (zh) 2011-07-20
AU2009313357B2 (en) 2015-06-11
HK1249053A1 (zh) 2018-10-26
EP2365828A4 (en) 2012-06-06
US20180094063A1 (en) 2018-04-05
US9834609B2 (en) 2017-12-05
US10689448B2 (en) 2020-06-23
MX2011000455A (es) 2011-02-25
RU2546254C9 (ru) 2015-07-10
JP5627591B2 (ja) 2014-11-19
PT2842573T (pt) 2017-12-04
RU2011141890A (ru) 2013-04-27
EP2365828A2 (en) 2011-09-21
PL2365828T3 (pl) 2015-04-30
ES2646168T3 (es) 2017-12-12
HRP20171640T1 (hr) 2018-01-12
EP3783024A1 (en) 2021-02-24
SI2842573T1 (en) 2018-01-31
DK2842573T3 (en) 2017-10-30
US20200347141A1 (en) 2020-11-05
ES2770134T3 (es) 2020-06-30
CA2733668C (en) 2022-08-30
US10138301B2 (en) 2018-11-27
WO2010054265A3 (en) 2010-09-16
US8101723B2 (en) 2012-01-24
JP6661734B2 (ja) 2020-03-11
PL2842573T3 (pl) 2018-04-30
JP2023116746A (ja) 2023-08-22
PL3290052T3 (pl) 2020-06-29
JP7301106B2 (ja) 2023-06-30
CA2733668A1 (en) 2010-05-14
US9382324B2 (en) 2016-07-05
JP2017019807A (ja) 2017-01-26
LT2842573T (lt) 2017-12-11
BRPI0917315A2 (pt) 2015-11-17
US20100196364A1 (en) 2010-08-05
US20230242650A1 (en) 2023-08-03
KR101699432B1 (ko) 2017-01-24
CA3166399A1 (en) 2010-05-14
EP2842573B1 (en) 2017-09-27
JP2019052165A (ja) 2019-04-04
JP6445496B2 (ja) 2018-12-26
AU2009313357A1 (en) 2010-05-14
DK2365828T3 (en) 2014-12-08
HUE035700T2 (en) 2018-05-28
BRPI0917315B1 (pt) 2020-12-08
EP3290052B1 (en) 2019-12-25
EP2365828B1 (en) 2014-10-15
EP2842573A1 (en) 2015-03-04
JP2014240385A (ja) 2014-12-25

Similar Documents

Publication Publication Date Title
ES2523740T3 (es) Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
ES2657226T3 (es) Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
RU2747735C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
CL2013003373A1 (es) Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll).
PE20191546A1 (es) Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb
PE20121817A1 (es) Anticuerpos antagonistas anti-notch3
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
NZ593853A (en) ANTI-cMET ANTIBODY
PE20211863A1 (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
RS54197B1 (en) NEW ANTIBODIES FOR THE INHIBITION OF C-MET DIMERIZATION AND THEIR USE
RU2020117210A (ru) Антитела к pd-l1, связывающие pd-l1 собаки
NZ585559A (en) Humanized antibodies against tl1a
NZ605980A (en) Anti-fap antibodies and methods of use
RS52919B (en) SCLEROSTINE BINDING AGENTS
NZ578943A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
NZ603045A (en) Tnf-alpha binding proteins
ATE452147T1 (de) Antikörper mit korrigierten cdr
NZ596042A (en) Humanized anti-factor d antibodies
RS52176B (en) HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
PE20211709A1 (es) Anticuerpos que reconocen tau
RU2014100111A (ru) МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
PE20220279A1 (es) Inhibidores especificos del complejo de ltbp de tgf beta y usos de los mismos
CO6180454A2 (es) Anticuerpos de la egfl7 y metodos de uso